A
Allarity Therapeutics, Inc.
ALLRCIK 0001860657NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-11.23M
Total Assets
$18.26M
Equity
$9.83M
Shares Out
15.82M
Op. Cash Flow
$-14.82M
Business
Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics using its Drug Response Predictor (DRP®) platform. It offers the DRP® companion diagnostic platform, develops the dual PARP/tankyrase inhibitor stenoparib, and provides gene expression and DRP analysis services to external biotech clients. Key business activities include therapeutic development (stenoparib), companion diagnostic development and validation, intellectual property management, and partnerships or out-licensing arrangements. Allarity conducts clinical trials and regulatory interactions in the U.S. and Europe, licenses rights worldwide, and delivers laboratory services to biotech partners.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 320,000 | 0 | — | — | — | |
| Research and development | 7 | 6 | 7 | 7 | 14 | |
| Impairment of intangible assets | 0 | 10 | 0 | 18 | — | |
| General and administrative | 6 | 11 | 10 | 10 | 12 | |
| Total operating expenses | 13 | 27 | 17 | 34 | 27 | |
| Loss from operations | −13 | −27 | −17 | −34 | −27 | |
| Interest income | 801,000 | 533,000 | 22,000 | 30,000 | — | |
| Interest expenses | −185,000 | −653,000 | −498,000 | — | — | |
| Foreign exchange gains (losses) | 757,000 | −212,000 | 133,000 | −913,000 | −95,000 | |
| Change in fair value adjustment of warrant derivative liabilities | 1,000 | 3 | 10 | — | — | |
| Total other income | 1 | 2 | 5 | 17 | 41,000 | |
| Loss before income tax expense (benefit) | −11 | −25 | −12 | −18 | — | |
| Income tax expense (benefit) | 0 | −381,000 | 83,000 | 2 | −133,000 | |
| Net loss | −11 | −25 | −12 | −16 | −27 | |
| Net loss attributable to common stockholders | −11 | −25 | −20 | −21 | — | |
| Net loss per common share, basic and diluted (in dollars per share) | −0.78 | −15.65 | −6,031 | −3,093 | −4.19 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 14 | 2 | 3,385 | 6,805 | 6 | |
| Change in cumulative translation adjustment | −667,000 | 57,000 | 300,000 | −121,000 | — | |
| Total comprehensive loss | −12 | −24 | −12 | −16 | −29 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash | 15 | 20 | 166,000 | — | — | |
| Receivables from ATM sales | 0 | 1 | 0 | — | — | |
| Other current assets | 265,000 | 115,000 | 209,000 | 2 | — | |
| Prepaid expenses | 2 | 507,000 | 781,000 | 591,000 | — | |
| Tax credit receivable | 866,000 | 770,000 | 815,000 | 789,000 | — | |
| Total current assets | 18 | 22 | 2 | 5 | — | |
| Property, plant and equipment, net | 330,000 | 309,000 | 20,000 | 21,000 | — | |
| Total assets | 18 | 23 | 12 | 15 | — | |
| Accounts payable | 4 | 4 | 8 | 6 | 5 | |
| Accrued expenses and other current liabilities | 3 | 5 | 1 | 2 | — | |
| Warrant derivative liability | 0 | 1,000 | 3 | 374,000 | — | |
| Income taxes payable | 81,000 | 74,000 | 59,000 | 41,000 | — | |
| Convertible promissory note and accrued interest | 1 | 1 | 1 | — | — | |
| Total current liabilities | 8 | 11 | 14 | 11 | — | |
| Total liabilities | 8 | 11 | 15 | 13 | — | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Common stock, $0.0001 par value (250,000,000 shares authorized); 19,030,619 and 7,302,797 shares issued and 16,080,980 and 7,302,797 outstanding at December 31, 2025, and December 31, 2024, respectively | 3,000 | 1,000 | 0 | — | — | |
| Additional paid-in capital | 144 | 131 | 90 | 83 | — | |
| Accumulated other comprehensive loss | −1 | −354,000 | −411,000 | −721,000 | — | |
| Accumulated deficit | −130 | −119 | −94 | −83 | — | |
| Treasury stock, at cost; 2,949,639 shares | −3 | 0 | — | — | — | |
| Total stockholders equity | 10 | 12 | −3 | −113,000 | — | |
| Total liabilities and stockholders equity | 18 | 23 | 12 | 15 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | −13,000 | 9,000 | — | — | — | |
| Intangible asset impairment | 0 | 10 | 0 | — | — | |
| Common stock issued for services | −200,000 | −336,000 | — | — | — | |
| Stock-based compensation expense | 482,000 | 71,000 | −71,000 | 2 | 6 | |
| Unrealized foreign exchange gain | 1 | −126,000 | −179,000 | 450,000 | 95,000 | |
| Non-cash interest expense | 185,000 | 230,000 | 464,000 | 138,000 | — | |
| Deferred income taxes | 0 | −446,000 | 97,000 | — | — | |
| Other current assets | −150,000 | 94,000 | 1 | −1 | −330,000 | |
| Unearned revenue | 0 | 207,000 | 0 | — | — | |
| Tax credit receivable | −96,000 | 45,000 | −26,000 | — | — | |
| Prepaid expenses | −2 | 274,000 | −190,000 | −618,000 | 130,000 | |
| Accounts payable | −1 | −4 | 2 | 6 | −1 | |
| Accrued liabilities | −3 | 4 | 43,000 | −5 | 7 | |
| Income taxes payable | 7,000 | 15,000 | 18,000 | −19,000 | 8,000 | |
| Net cash used in operating activities | −15 | −17 | −13 | −17 | −15 | |
| Purchase of property and equipment | −8,000 | −298,000 | 0 | −18,000 | — | |
| Net cash used in investing activities | −8,000 | −298,000 | 0 | 791,000 | 1 | |
| Proceeds from 3i promissory notes | 0 | 1 | 1 | 1 | — | |
| Repayment of 3i debt | 0 | −1 | −4 | — | — | |
| Proceeds from ATM sales of common stock, net of issuance costs | 11 | 37 | 0 | — | 32 | |
| Net proceeds from common stock and pre-funded warrant issuance | 3 | 0 | 17 | — | — | |
| Proceeds from issuance of Convertible Redeemable Series A Preferred Stock | 0 | 3 | 1 | — | — | |
| Redemption of Convertible Redeemable Series A Preferred Stock | 0 | −4 | — | — | — | |
| Common stock repurchase | −3 | 0 | — | — | — | |
| Net cash provided by financing activities | 11 | 37 | 11 | −1 | 34 | |
| Net increase (decrease) in cash | −4 | 19 | −2 | −17 | — | |
| Effect of exchange rate changes on cash | −667,000 | 225,000 | −113,000 | −189,000 | −680,000 | |
| Cash paid for interest | 0 | 423,000 | 34,000 | 85,000 | 262,000 | |
| Cash received for interest | 801,000 | 503,000 | — | — | — | |
| Stock issued in conjunction with consulting agreement | 200,000 | 90,000 | 0 | — | 3 | |
| Conversion of Series A Redeemable Preferred Stock to common stock | 0 | 2 | 4 | 1 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro